Article
Neonatal lethality in knockout mice expressing the kinase-dead form of the gefitinib target GAK is caused by pulmonary dysfunction.
PloS one - 1 Jan 2011
Tabara Hiroe, Naito Yoko, Ito Akihiko, Katsuma Asako, Sakurai Minami A, Ohno Shouichi, Shimizu Hiroyuki, Yabuta Norikazu, Nojima Hiroshi
Abstract excerpt
Gefitinib (Iressa) is an inhibitor of the epidermal growth factor receptor (EGFR) that has shown promising activity in the treatment of patients with non-small cell lung cancer (NSCLC). However, adverse side effects of gefitinib treatment, such as respiratory dysfunction, have limited the therapeutic benefit of this targeting strategy. The present results show that this adverse effect can be attributed to the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
